Back to results
US 2025/0084170 A1Published application
Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof
OwnerSeung Yong SEONG, Sang Beum LEE +1inventors
InventorsSeung Yong SEONG, Sang Beum LEE, Jeong Hwan KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to a bispecific humanized single domain antibody targeting both PD-L1 and CD47, as well as uses thereof. Specifically, a humanized single domain antibody that binds bispecifically to PD-L1 and CD47, which are immune checkpoint proteins, has been developed, and its efficacy has been confirmed both in vitro and in vivo. Therefore, the bispecific humanized single domain antibody can be effectively used as an immune checkpoint inhibitor for immuno-oncology therapy.
Claims20
A bispecific antibody that binds bispecifically to PD-L1 and CD47, comprising:
- a first humanized single domain antibody (first hsdAb) or an antigen-binding fragment thereof, which specifically binds to PD-L1;
- and a second humanized single domain antibody (second hsdAb) or an antigen-binding fragment thereof, which specifically binds to CD47.
Dependencies are inferred from the claim text.